title: Binding to the low-density lipoprotein receptor accelerates futile catalytic cycling in PCSK9 and raises the equilibrium level of intramolecular acylenzyme.
abstract: Proprotein convertase subtilisin-kexin type 9 (PCSK9) binds to the low-density lipoprotein receptor (LDLR) on target cells and lowers the level of receptor by impeding its recycling. PCSK9 is self-processed to a complex of its prodomain and catalytic domain like a typical protein convertase, but it does not develop normal proteolytic activity. Instead, its propeptide remains complexed with the catalytic domain, and the C-terminal Gln152 of the prodomain occupies the active site like a substrate for peptide synthesis. To probe its latent catalytic activity, PCSK9 and its complex with the soluble LDLR extracellular domain were separately transferred into H218O, and time point samples were analyzed by peptide mapping with mass spectrometry to measure the rate and extent of incorporation of 18O into the Gln152 carboxylate. In free wild-type or D374Y mutant PCSK9, the t1/2 for exchange of 18O for both oxygens was near 5 min. This slow process progressed to completion, with the distribution of oxygen isotopes in the Gln152 carboxylate finally matching that in solvent. In contrast, exchange reached its final state in <30 s in LDLR-complexed D374Y mutant PCSK9, but approximately 40% of the molecules gave data indicating the presence of only one 18O atom in Gln152. With support from further experiments, this was attributed to hydrolysis of acylenzyme in H216O during preparations for digestion and indicated that PCSK9 complexed with LDLR contains approximately 40% intramolecular acylenzyme at equilibrium. The synthetic EGF-A domain of LDLR induced similar effects as the full-length receptor. The data suggest the existence of distinct conformational states in free and receptor-bound PCSK9.
authors.affiliation: Pfizer Global Research and Development, Groton, Connecticut 06340, USA. kieran.f.geoghegan@pfizer.com
authors.forename: Kieran F
authors.initials: KF
authors.lastname: Geoghegan
authors.forename: Lise R
authors.initials: LR
authors.lastname: Hoth
authors.forename: Alison H
authors.initials: AH
authors.lastname: Varghese
authors.forename: Wen
authors.initials: W
authors.lastname: Lin
authors.forename: James G
authors.initials: JG
authors.lastname: Boyd
authors.forename: Matthew C
authors.initials: MC
authors.lastname: Griffor
mesh_terms: D000818:Animals; D055162:Biocatalysis; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D005973:Glutamine / Q000378:metabolism; D006801:Humans; D007554:Isotopes; D013058:Mass Spectrometry; D050505:Mutant Proteins / Q000737:chemistry / Q000378:metabolism; D010455:Peptides / Q000737:chemistry / Q000378:metabolism; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D011973:Receptors, LDL / Q000378:metabolism*; D012697:Serine Endopeptidases / Q000737:chemistry / Q000378:metabolism*; D015219:Substrate Cycling
chemical_list: D007554:Isotopes; D050505:Mutant Proteins; D010455:Peptides; D011973:Receptors, LDL; D005973:Glutamine; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; D043484:Proprotein Convertases; D012697:Serine Endopeptidases